UROREC Hard capsule (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Urorec 4 mg hard capsules.
Qualitative and quantitative composition
Each hard capsule contains 4 mg silodosin. For the full list of excipients, see section 6.1.
Pharmaceutical form
Hard capsule. Yellow, opaque, hard gelatin capsule, size 3.
Therapeutic indications
Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men.
Posology and method of administration
Posology The recommended dose is one capsule of Urorec 8 mg daily. For special patient populations, one capsule of Urorec 4 mg daily is recommended (see below). Elderly No dose adjustment is required in ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
Intraoperative Floppy Iris Syndrome (IFIS) IFIS (a variant of small pupil syndrome) has been observed during cataract surgery in some patients on α<sub>1</sub>-blockers or previously treated with α<sub> ...
Interaction with other medicinal products and other forms of interaction
Silodosin is metabolised extensively, mainly via CYP3A4, alcohol dehydrogenase and UGT2B7. Silodosin is also a substrate for P-glycoprotein. Substances that inhibit (such as ketoconazole, itraconazole, ...
Fertility, pregnancy and lactation
Pregnancy and breast-feeding Not applicable as silodosin is intended for male patients only. Fertility In clinical studies, the occurrence of ejaculation with reduced or no semen has been observed during ...
Effects on ability to drive and use machines
Urorec has minor or moderate influence on the ability to drive and use machines. Patients should be informed about the possible occurrence of symptoms related to postural hypotension (such as dizziness) ...
Undesirable effects
Summary of the safety profile The safety of silodosin has been evaluated in four Phase II-III double-blind controlled clinical studies (with 931 patients receiving silodosin 8 mg once daily and 733 patients ...
Overdose
Silodosin was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse reaction was postural hypotension. If ingestion is recent, induction of vomiting or gastric lavage ...
Pharmacodynamic properties
Pharmacotherapeutic group: Urologicals, alpha-adrenoreceptor antagonists ATC code: G04CA04 Mechanism of action Silodosin is highly selective for α<sub>1A</sub>-adrenoreceptors that are primarily located ...
Pharmacokinetic properties
The pharmacokinetics of silodosin and its main metabolites have been evaluated in adult male subjects with and without BPH after single and multiple administrations with doses ranging from 0.1 mg to 48 ...
Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, carcinogenic, mutagenic and teratogenic potential. Effects in animals (affecting the thyroid ...
List of excipients
Capsule content: Starch, pregelatinised (maize) Mannitol (E421) Magnesium stearate Sodium laurilsulfate Capsule shell: Gelatin Titanium dioxide (E171) Yellow iron oxide (E172)
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years.
Special precautions for storage
Do not store above 30°C. Store in the original package in order to protect from light and moisture.
Nature and contents of container
The capsules are provided in PVC/PVDC/aluminium foil blisters, packed in cartons. Packs of 5, 10, 20, 30, 50, 90, 100 capsules. Not all pack sizes may be marketed.
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Recordati Ireland Ltd., Raheens East, Ringaskiddy Co. Cork, Ireland
Marketing authorization number(s)
EU/1/09/608/001 EU/1/09/608/002 EU/1/09/608/003 EU/1/09/608/004 EU/1/09/608/005 EU/1/09/608/006 EU/1/09/608/007
Date of first authorization / renewal of the authorization
Date of first authorisation: 29/01/2010 Date of latest renewal: 18/09/2014
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
